Stockwinners Market Radar for October 22, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:06 EDT Euronet reports Q3 adjusted EBITDA $227.3M vs. $181.4M last year - Reports Q3 transaction 1.23B, up 21% from last year.

18:55 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Manhattan Associates (MANH) up 6.3%... Teradyne (TER) up 5.7%... Carlisle Companies (CSL) up 5.3%... Usana (USNA) up 3.3%... Navient (NAVI) up 1.2%... Discover Financial (DFS) up 0.6%. ALSO HIGHER: Hanger (HNGR) up 11.1% after entering S&P SmallCap600 index... Moderna (MRNA) up 4.0% after getting FDA fast track designation for mRNA-3927. DOWN AFTER EARNINGS: Resideo (REZI) down 28.2%... iRobot (IRBT) down 19.1%... Texas Instruments (TXN) down 9.8%, Intel (INTC) down 1.7%, Analog Devices (ADI) down 3.6%, Broadcom (AVGO) down 2.3%, Nvidia (NVDA) down 2.2%, Qualcomm (QCOM) down 1.8%, AMD (AMD) down 1.6% in sympathy... Hawaiian Holdings (HA) down 6.6%... Six Flags (SIX) down 5.7%... Whirlpool (WHR) down 4.7%... Boyd Gaming (BYD) down 3.7%... Chipotle (CMG) down 1.9%... Snap (SNAP) down 1.5%... Skechers (SKX) down 1.3%. ALSO LOWER: Soleno Therapeutics (SLNO) down 20.0% after equity offering... ServiceNow (NOW) down 9.2% after CEO departure to lead Nike (NKE). Movers as of 18:30ET.

18:42 EDT Logitech CEO: We had a solid quarter despite macroeconomic noise - In an interview on CNBC's Mad Money, Logitech CEO Bracken Darrell said: We expect Video Collaboration to eventually be a billion dollar business... We are a portfolio of peripherals for cloud services... We've been in China for 25 years... We have a great market in China, it's our number two market... We are taking concerted efforts to mitigate the tariffs.

17:57 EDT Teradyne jumps 6% after quarterly results, guidance based on 5G demand - Shares of semiconductor equipment maker Teradyne are up 5.7% to $62.50 in after-hours trading. "In Q4, our strong outlook is driven mainly by continued 5G and memory related Semiconductor Test demand and improved storage test shipments," said CEO Mark Jagiela. Jagiela added . "For the full year, at the mid-point of our guidance, we expect our year-over-year sales to grow more than 7% to over $2.2 billion and non-GAAP earnings per share to grow 16%."

17:33 EDT Granite Construction awarded $15M airfield contract in North Carolina - Granite announced that GWWH, the joint venture team comprised of Granite, Webcor Construction LP, Weeks Marine, Inc., and Healy Tibbitts Builders, Inc. has been awarded a $15M design build contract by the United States Coast Guard for the Recapitalize Airfield Pavements and Airfield Lighting Project in Elizabeth City, North Carolina. Granite's scope of work includes pavement rehabilitation; lighting and signage, supporting various taxiways and aprons, construction of an electrical duct bank and reconstruction of the existing concrete helipad. Design is underway with construction scheduled to begin in summer 2020 and be complete in summer 2021.

17:31 EDT Snap says average revenue per user was $2.12 in Q3, an increase of 33% y-o-y - Says maps and gaming are important opportunities for growth. Says focused on scaling content and augmented reality platforms in short term. Say will work towards competing in wearable augmented reality technology in long term. Says using Spectacles 3 to learn more about wearable computing. Says delivering fast visual communication better than ever before. Says remains undermonitized in terms of audience and engagement. Says extended the maximum length of video ads on its platform, allowing advertisers to leverage videos up to three minutes in length. Says continues to benefit from an improved Android application. Comments taken from Q3 earnings conference call.

17:28 EDT Resideo begins comprehensive operational and financial review - Resideo has begun a comprehensive operational and financial review, focused on improving gross margins and optimizing its organizational footprint. The aim of the review is to simplify internal processes that will enable Resideo to be more agile in responding to changing customer and marketplace dynamics. The company has retained industry-recognized experts in supply chain optimization and organizational excellence to assist in the review. The review will build upon the previously announced cost optimization program, which is on track to achieve approximately $15 million in realized savings in 2019 and $50 million in run-rate savings by the end of 2020. The new operational and financial review is expected to capture incremental gross margin and operating expense savings in 2020. The company said it believes significant gross margin opportunity exists in Comfort and Security products through value engineering cost reductions. Resideo plans to provide a detailed report of planned actions, anticipated timelines, and progress made to date in conjunction with the announcement of its fourth-quarter and full-year 2019 financial results, expected in February 2020. "While I am disappointed in our preliminary results for the third quarter, we remain confident in the fundamentals of our business," said Mike Nefkens, president and CEO of Resideo. "The issues impacting our second-half 2019 results underscore the urgency to simplify our operations, reduce our cost structure, increase agility throughout the organization and drive adoption of our products in the professional, do-it-for-me channel where Resideo is a market leader. We are aggressively addressing challenges through a comprehensive operational and financial review of the company, with a particular focus on the Products & Solutions segment. We are targeting areas to drive improved financial performance and are confident we are pursuing the necessary changes to deliver superior shareholder value."

17:06 EDT Epsilon Energy CEO comments on recent well results - Michael Raleigh, CEO, commented, "As previously announced by the company, the operator has completed all four lower Marcellus wells which began drilling on June 26th,, 2019. These wells are currently in the flow-back testing phase with gross aggregate production ranging from 45 to 50 MMcf/d. This represents approximately 13 MMcf/d net to Epsilon's working interests and when added to our existing production should provide for 35-36 MMcf/d of total working interest gas deliverability in November. This is a very welcome incremental 56% production increase heading into the usually constructive NE winter demand period. We originally planned to have this production turn in line in December. We will schedule a meeting to discuss our 2020 capital budget with our operating partner prior to year-end to plan next year's development program. At the current strip, we anticipate achieving high single digit yr/yr production growth at an attractive rate of return within our forecast cash flow. We continue to buy-back our stock under the previously announced program and have acquired 395,487 shares to date which reduces the total shares available to the public to 26.985 MM shares."

17:04 EDT Golden Star Resources to move corporate office, CFO Andre van Niekerk to leave - Golden Star Resources announced that it plans to close its Toronto office by April 30, 2020 and that its executive team will be located in London, England. Andre van Niekerk, executive VP and CFO, has decided not to accept the offer to move to London and expects to leave the company by April 30, 2020.

17:01 EDT AptarGroup says Activ-Blister packaging solution approved by FDA - AptarGroup announced that its Activ-Blister packaging solution for oral solid dose drug delivery was recently approved by the FDA for a HIV prevention medicine.

16:57 EDT Semiconductor stocks fall after Texas Instruments gives dismal outlook - Shares of Market Vectors Semiconductor ETF (SMH) arer down 3% in after-hours trading. Texas Instruments (TXN) is down 9%. Other semiconductor stocks including Intel (INTC), Nvidia (NVDA), Qualcomm (QCOM), TSMC (TSM) Broadcom (AVGO), Nvidia (NVDA), ASML (ASML), Analog Devices (ADI), Lam Research (LRCX) and AMD (AMD) are under pressure in post-market trading.

16:37 EDT K12 reports Q1 adjusted EBITDA $3.3M vs. $8.8M last year - Reports Q1 Enrollment in Managed Public School Programs up 3.5% at 122.3K. Reports Q1 Managed Public School Programs revenue per average enrollment up 4% at $1,860.

16:33 EDT DoD's Esper removes himself from JEDI contract review, citing son's work - Statement From Chief Pentagon Spokesperson Jonathan Rath Hoffman on DoD Cloud Update: "As you all know, soon after becoming Secretary of Defense in July, Secretary Esper initiated a review of the Department's cloud computing plans and to the JEDI procurement program. As part of this review process he attended informational briefings to ensure he had a full understanding of the JEDI program and the universe of options available to DoD to meet its cloud computing needs. Although not legally required to, he has removed himself from participating in any decision making following the information meetings, due to his adult son's employment with one of the original contract applicants. Out of an abundance of caution to avoid any concerns regarding his impartiality, Secretary Esper has delegated decision making concerning the JEDI Cloud program to Deputy Secretary Norquist. The JEDI procurement will continue to move to selection through the normal acquisition process run by career acquisition professionals." The fly notes that Amazon (AMZN) and Microsoft (MSFT) are currently bidding on the contract reportedly worth up to $10B. Reference Link

16:27 EDT Healthcare Services declares 20c per share quarterly cash dividend - The Company's Board of Directors declared a quarterly cash dividend of $0.20 per common share, payable on December 27, 2019 to shareholders of record at the close of business on November 22, 2019. This represents the 66th consecutive quarterly cash dividend payment, as well as the 65th consecutive increase since the initiation of quarterly cash dividend payments in 2003.

16:25 EDT Discover reports Q3 30+ day delinquency rates for credit card loans up 18bps - In the company's Direct Banking segment, Q3 net interest margin was 10.43%, up 15 basis points versus the prior year. The 30+ day delinquency rate for credit card loans was 2.50%, up 18 basis points from the prior year and up 16 basis points from the prior quarter. The credit card net charge-off rate was 3.32%, up 18 basis points from the prior year and down 17 basis points from the prior quarter. The student loan net charge-off rate, excluding PCI loans, was 0.69%, down 50 basis points from the prior year and down 4 basis points from the prior quarter. The personal loans net charge-off rate of 3.99% was down 10 basis points from the prior year and down 34 basis points from the prior quarter. The higher overall net charge-off rate was primarily due to the seasoning of recent years' loan growth and supply-driven credit normalization. Provision for loan losses of $799M increased $57M from the prior year as higher net charge-offs were slightly offset by a lower reserve build. The reserve build for the third quarter of 2019 was $98 million, compared to a reserve build of $100M in the third quarter of 2018.

16:22 EDT Discover CEO says will achieve all elements of FY19 guidance - CEO Roger Hochschild says: "We had a strong third quarter, achieving key objectives for loan growth, margin expansion and credit performance, against the backdrop of continued stability in the consumer sector of the U.S. economy. We continued to invest in our operating model with the objective of driving sustained profitable growth and solid returns." Hochschild added, "Once again this quarter we generated an outstanding return on equity of 26%, reflecting the strength of our business model. Looking ahead to the fourth quarter, we expect to finish the year on a very solid footing, achieving all elements of our 2019 financial and operational guidance."

16:21 EDT C&J Energy Services and Keane Group shareholders approve merger - C&J Energy Services (CJ) and Keane Group (FRAC) announced that the shareholders of both companies approved all of the proposals necessary for the closing of the previously announced all-stock merger of equals between Keane and C&J. The merger of equals is anticipated to close on October 31 following the satisfaction of other customary closing conditions. At the special meeting of C&J shareholders held today in Houston, Texas, C&J shareholders voted to approve the pending transaction with Keane. Approximately 83% of the outstanding shares of C&J common stock voted at the C&J special meeting, with more than 99% of the votes cast in favor of adoption of the merger agreement.

16:20 EDT ServiceNow maintains FY19 margin guidance - ServiceNow is maintaining its FY19 margin guidance as follows: subscription gross margins of 86%, operating margin of 21% and free cash flow margin of 28%.

16:19 EDT Texas Instruments down 7.5% to $119.00 after Q4 guidance trails estimates - The company reported mixed Q3 results.

16:16 EDT ServiceNow names Bill McDermott as new CEO - ServiceNow announced that Bill McDermott will join ServiceNow by year-end 2019 as President and CEO and a member of the Board of Directors. McDermott will succeed John Donahoe, who is stepping down from ServiceNow to become President and Chief Executive Officer of Nike in January 2020. To ensure a smooth transition, Donahoe will remain ServiceNow's CEO through the transition period and will retain his seat on the company's Board of Directors for the remainder of his current term, ending in June 2020. McDermott served as CEO of SAP from 2014 until this month and was co-CEO from 2010 to 2014.

16:15 EDT Moderna receives FDA fast track designation for mRNA-3927 - Moderna announced that the U.S. Food and Drug Administration has granted Fast Track designation for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia. The company announced the open IND for mRNA-3927 on September 30, 2019. "Propioic acidemia is caused by the inability of the body to breakdown certain proteins and fats which leads to the build-up of toxic chemicals. The disease is characterized by life-threatening illnesses in response to minor stressors, neurological dysfunction and cardiomyopathy," said George Diaz, M.D., Ph.D., chief, division of medical genetics, Icahn School of Medicine at Mount Sinai Hospital. "Currently there are no approved therapies available that treat the underlying cause of this debilitating disease."

16:14 EDT Whirlpool CEO says 'our fundamentals remain strong' - "We have sustained momentum towards achieving our long-term financial goals despite global economic volatility and remain committed to our robust strategy for creating shareholder value," said Marc Bitzer, chairman and CEO of Whirlpool Corporation. "Our fundamentals remain strong, and we made solid progress against our stated priorities with near-break even performance in EMEA and strong results in North America."

16:13 EDT Chipotle sees 150 to 165 new restaurant openings in 2020

16:13 EDT Flowserve to provide equipment for two reverse osmosis desalination projects - Flowserve Corporation announced that it recently signed agreements to provide the main pumps for two large sea water reverse osmosis (SWRO) desalination plants, Taweelah and Rabigh-3. Once completed, the Taweelah plant, located just outside of Abu Dhabi, United Arab Emirates (UAE), will be the largest SWRO project in the world and have the capacity to process 909,200 cubic meters of water per day (m3/day). The new Rabigh-3 facility will serve the Jeddah and Mecca areas in the Kingdom of Saudi Arabia and will have an initial capacity of 600,000 m3/day. Flowserve will provide more than 135 pumps, including key products such as High Pressure (HP) pumps, HP and ERD boosters and second pass HP pumps to the Rabigh-3 and Taweelah projects. In close collaboration with the customer and other stakeholders, Flowserve has provided a pump solution that is well positioned to meet performance expectations throughout all services.

16:11 EDT Nike names John Donahoe as new CEO - The board of NIKE (NKE) announced that John Donahoe will be appointed as the company's new President and CEO, effective Jan. 13, 2020. At the same time, Mark Parker, CEO since 2006 and Chairman, President & CEO since 2016, will become Executive Chairman and continue to lead the board and work closely with Donahoe and the senior management team. Donahoe is the current President and CEO of ServiceNow (NOW). and also serves on its Board of Directors. He is Chairman of PayPal Holdings, Inc.

16:10 EDT Amgen declares Q4 dividend of $1.45 per share - The dividend will be paid on Dec. 6, to all stockholders of record as of the close of business on Nov. 15.

16:08 EDT Texas Instruments CEO says 'most markets weakened further' - Rich Templeton, TI's chairman, president and CEO, made the following comments: "Revenue decreased 11% from the same quarter a year ago, as most markets weakened further. In our core businesses, Analog revenue declined 8% and Embedded Processing declined 19% from the same quarter a year ago. Our cash flow from operations of $7.0 billion for the trailing 12 months again underscored the strength of our business model. Free cash flow for the trailing 12 months was $6.0 billion and 41% of revenue. This reflects the quality of our product portfolio, as well as the efficiency of our manufacturing strategy, including the benefit of 300-millimeter Analog production. We have returned $7.4 billion to owners in the past 12 months through stock repurchases and dividends. Over the last 12 months, our dividends represented 48% of free cash flow, underscoring their sustainability. In September, we announced we would increase our dividend by 17%. Together, our stock repurchases and dividends reflect our continued commitment to return all free cash flow to our owners. TI's fourth quarter outlook is for revenue in the range of $3.07 billion to $3.33 billion, and earnings per share between $0.91 and $1.09, which includes an estimated $5 million discrete tax benefit. We continue to expect our annual operating tax rate to be about 16% in 2019."

16:06 EDT Boyd Gaming backs FY19 total adjusted EBITDAR of $885M-$910M

16:03 EDT Hawaiian Holdings sees Q4 ASMs up 3.0%-4.5% - Sees Q4 Operating revenue per ASM down 0.5%-3.5%.

16:02 EDT AngioDynamics announces departure of CFO Michael Greiner, affirms FY20 outlook - AngioDynamics announced that Michael Greiner, Executive Vice President and CFO will be departing the Company. Stephen A. Trowbridge, Senior Vice President and General Counsel, will assume the role of interim CFO in addition to his current responsibilities. Mr. Greiner will remain with AngioDynamics to facilitate a smooth transition of duties up to the filing of the second fiscal quarter 10-Q, and the company has initiated a process to determine a permanent successor. The company is reaffirming its previously issued financial guidance for FY020.

15:17 EDT Boeing confirms Deal to succeed McAllister as CEO of Boeing Commercial Airplanes - Boeing named Stan Deal to succeed Kevin McAllister as president and CEO of Boeing Commercial Airplanes and Ted Colbert to succeed Deal as president and CEO of Boeing Global Services, effective immediately. Vishwa Uddanwadiker is appointed to Colbert's former role as interim chief information officer and senior vice president of Information Technology & Data Analytics. Boeing President and CEO Dennis Muilenburg said: "Stan brings extensive operational experience at Commercial Airplanes and trusted relationships with our airline customers and industry partners; and Ted brings to our Global Services business an enterprise approach to customers and strong digital business expertise-a key component of our long-term growth plans. We're grateful to Kevin for his dedicated and tireless service to Boeing, its customers and its communities during a challenging time, and for his commitment to support this transition. We also thank Vishwa for stepping up to this important role." Boeing Chairman David Calhoun said: "The Boeing board fully supports these leadership moves. Boeing will emerge stronger than ever from its current challenges and the changes we're making throughout Boeing will benefit the flying public well into the future."

13:38 EDT ATA says truck tonnage index rose 0.2% in September - American Trucking Associations' advanced seasonally adjusted For-Hire Truck Tonnage Index increased 0.2% in September after falling 4% in August. In September. "This was the first month in 2019 that we did not see a significant increase or decrease in tonnage," said ATA Chief Economist Bob Costello. "For the entire third quarter, the index was up 1.2% over the previous quarter and 4.5% from a year earlier, both are nice gains." It is important to note that ATA's tonnage data is dominated by contract freight, which is performing significantly better than the plunge in spot market freight this year. August's reading was revised down compared with our September press release. Compared with September 2018, the SA index increased 3.5%. The index is up 4.1% year-to-date compared with the same period last year. Publicly traded companies in the space include ArcBest (ARCB), J.B. Hunt (JBHT), Knight-Swift (KNX), Old Dominion (ODFL), Swift Transportation (SWFT) and Werner (WERN).

13:19 EDT Disney CEO says Verizon deal will 'jumpstart' subscriptions significantly - Bob Iger is speaking on CNBC.

13:02 EDT Bombardier announces PSP pact with GE Aviation - Bombardier (BDRBF) announced a Preferred Service Provider agreement with GE Aviation (GE). As of today, GE will power Bombardier's cockpit and cabin connectivity solutions - including new, curated, service bundles that will simplify the selection of cockpit and cabin services with tip-to-tail solutions for new and in-service aircraft. This agreement is a first step toward the launch of Bombardier's comprehensive Smart Link Plus connected aircraft program. Launching in the second half of 2020, Smart Link Plus will help Bombardier customers drive operations and maintenance decisions by leveraging fleet-wide data, the Canadian company said. GE Aviation is also working closely with Bombardier on the development of the Smart Link Plus box - a Health Monitoring Unit "smart" box capable of generating key data for customers, enabling them to increase operational efficiency, and minimize return-to-service times through data-driven decisions.

12:40 EDT Senators introduce bill to encourage competition in social media - U.S. Senators Mark R. Warner, Josh Hawley, and Richard Blumenthal will introduce the Augmenting Compatibility and Competition by Enabling Service Switching, or ACCESS, Act, bipartisan legislation that will encourage market-based competition to dominant social media platforms by requiring the largest companies to make user data portable - and their services interoperable - with other platforms, and to allow users to designate a trusted third-party service to manage their privacy and account settings, if they so choose. The Augmenting Compatibility and Competition by Enabling Service Switching Act would increase market competition, encourage innovation, and increase consumer choice by requiring large communications platforms to: Make their services interoperable with competing communications platforms; Permit users to easily port their personal data in a structured, commonly used and machine-readable format; Allow users to delegate trusted custodial services, which are required to act in a user's best interests through a strong duty of care, with the task of managing their account settings, content, and online interactions. Publicly traded companies that could be affected by this measure include Facebook (FB), Twitter (TWTR), Alphabet (GOOG), and Snap (SNAP). Reference Link

12:13 EDT S&P lowers Boeing outlook to Negative on Stable on 737 MAX concerns - S&P Global Ratings affirmed its ratings on Boeing, including the "A" issuer credit rating, and revised its outlook to Negative from Stable. The outlook revision reflects "concerns that recent reports that Boeing may have misled the FAA about the problems with the 737 MAX MCAS software that likely caused two accidents could have wide-ranging effects on the company's competitive and financial positions," the ratings agency said in statement. The Negative outlook reflects "potential lasting damage" from the 737 MAX grounding, that could weaken Boeing's competitive position and make it difficult to maintain funds from operations to debt above 40% after deliveries resume, "absent a more conservative financial policy," added S&P.

12:05 EDT S&P revises outlook on Boeing

12:00 EDT Howard Hughes falls -16.0% - Howard Hughes is down -16.0%, or -$20.58 to $107.80.

12:00 EDT Cision rises 19.0% - Cision is up 19.0%, or $1.60 to $10.05.

12:00 EDT Teekay Corp. rises 23.5% - Teekay Corp. is up 23.5%, or 96c to $5.06.

11:33 EDT Elasticsearch Service available on Google Cloud Marketplace - Elastic (ESTC) announced the general availability of its Elasticsearch Service on GCP Marketplace (GOOG). Earlier this year, Elastic announced a deeper partnership with Google to make the Elasticsearch Service on Elastic Cloud more accessible to Google Cloud Platform, GCP, users. Today, Elastic is realizing the first milestone in this initiative: the general availability of the Elasticsearch Service on GCP Marketplace following a successful beta with key customers. GCP customers can now subscribe to Elastic's Elasticsearch Service through GCP Marketplace, simplifying procurement with consolidated billing through their GCP account. Also, GCP customer consumption of the Elasticsearch Service via the marketplace counts toward GCP committed use. GCP users can now subscribe to the Elasticsearch Service through the GCP Marketplace and get access to the same exclusive features that only Elastic can offer, including Elastic SIEM, APM, Logs, Metrics, and more. "The release of billing integration for the Elasticsearch Service on the GCP marketplace gives our users a simple path to consume the Elasticsearch Service from their Google Cloud account. We're committed to providing our mutual customers with the best possible experience on Google Cloud. This is one of several key benefits ensuring seamless interoperability that is a result of our collaboration," said Manvinder Singh, Director, Partnerships at Google Cloud.

11:24 EDT McDonald's sees Q4 foreign currency impact of 1c-3c - Sees FY19 foreign currency impact of 20c-22c.

11:17 EDT Hanover Insurance appoints Denise Lowsley as CHRO - The Hanover Insurance Group announced Denise Lowsley has been appointed EVP and chief human resources officer. Lowsley will work closely with The Hanover's executive leaders, members of the human resources leadership team, and others across the organization to drive the company's human capital strategy and collaborative culture forward. She joins The Hanover from The Navigators Group, where she was SVP and CHRO.

11:17 EDT Teekay and Teekay LNG announce resolution to China LNG joint venture issues - Teekay Corporation (TK) and Teekay LNG Partners (TGP) announced that COSCO Shipping Energy Transportation Co., Ltd. has completed an ownership restructuring on arms-length terms which has resulted in Teekay LNG's joint venture partner, China LNG Shipping, no longer being classified as a "Blocked Person" under Office of Foreign Assets Control, or OFAC, rules. Accordingly, Teekay LNG's 50/50 joint venture with China LNG, which owns four on-the-water ARC7 LNG carriers and two ARC7 LNG carrier newbuildings, is also no longer classified as a "Blocked Person" under OFAC rules. The four existing ARC7 LNG carriers are continuing to operate under their long-term contracts transporting gas from the Yamal LNG project and the remaining two ARC7 LNG carrier newbuildings are expected to deliver in the fourth quarter of 2019. As a result of the resolution of this issue, the Teekay Group is now planning to reschedule its previously-postponed investor and analyst meeting and expects to provide details soon, the company announced.

11:15 EDT Lockheed Martin does not see impact to outlook from current budget CR - Lockheed Martin management says programs are "well-supported" by proposed U.S. budget. Comments provided during Q3 earnings conference call.

11:10 EDT McDonald's says still expects to complete about 2,000 EOTF locations this year - Comments taken from Q3 earnings conference call.

10:50 EDT InterDigital rallies after reaching patent, settlement agreement with ZTE - InterDigital (IDCC) disclosed earlier in a regulatory filing that on October 18, it entered into a "multi-year, worldwide, non-exclusive, royalty-bearing" patent license and settlement agreement with ZTE Corporation (ZTCOY) and agreed to resolve virtually all of their existing disputes. The agreement covers the sale of ZTE's 3G, 4G and 5G handset and tablet products, as well as 802.11 and HEVC technologies incorporated in such products, and includes a partial release by InterDigital of claims of past infringement by ZTE, the company said. InterDigital and ZTE have agreed to terms for dismissal of all outstanding litigation and other proceedings among them and their affiliates. ZTE has also agreed to withdraw from all proceedings related to the Inter Partes Review of U.S. Patent No. 8,380,244, including the pending appeal before the U.S. Court of Appeals for the Federal Circuit, and to request the termination of or withdraw from any other invalidation or opposition proceedings it has initiated against InterDigital. InterDigital added that it has retained the right to continue to participate in any such IPR, invalidation or opposition proceedings, including any appeals. Shares of InterDigital are up 4%, or $2.04, to $55.15 in morning trading.

10:45 EDT JetBlue concerned about current, future tariff environment - Management noted it isn't changing the company's current FY19 or FY20 delivery assumptions due to tariffs. Management does, however, view tariff impacts as temporary.

10:36 EDT JetBlue 'confident' in low single-digit RASM growth in FY20

10:26 EDT Carnival, Royal Caribbean, government of St. Lucia sign MOU - Carnival Corporation (CCL) and Royal Caribbean Cruises Ltd. (RCL) announced the signing of a memorandum of understanding with the government of Saint Lucia to form a joint venture to manage the existing cruise pier and terminal facilities in Saint Lucia, and to design, construct and operate a new cruise port on the island. As part of the MOU, Carnival Corporation and Royal Caribbean and the government of Saint Lucia will establish a long-term concession agreement to formalize the terms and responsibilities for the joint venture to manage and operate the current cruise pier and terminal facilities at the Port of Castries. "Additionally, the joint venture will design, finance, construct and operate a new cruise port in Vieux Fort on the southern part of the island that will be able to accommodate the latest and most innovative ships in the cruise industry," the companies said in a statement.

10:23 EDT Liberty Global down 7% after Sunrise cancels Extraordinary General Meeting - Class A shares of Liberty Global plc (LBTYA, LBTYB and LBTYK) are down about 7% in early trading after the company announced earlier that it supports the cancellation of Sunrise Communications' Extraordinary General Meeting, or EGM, which had been scheduled to take place Wednesday, October 23. "Sunrise was seeking approval for an ordinary capital increase by way of a rights offering to finance its pending acquisition of UPC Switzerland. Sunrise has reviewed the vote tally, including the intention of its largest shareholder Freenet to vote against the deal, and determined that the proposal was unlikely to be approved by shareholders. The existing share purchase agreement between the parties will remain in place with some minor amendments, including the flexibility to convene a new EGM and certain adjusted termination rights. In addition, the commitments by Liberty Global in the recently announced Conditional Rights Purchase Agreement will lapse and thereby terminate," Liberty Global stated. On February 27, Liberty Global plc had announced a binding agreement to sell its Swiss operation, UPC Switzerland, to Sunrise Communications Group AG for a total enterprise value of $6.3B on a U.S. GAAP basis.

10:15 EDT Kimberly-Clark says to provide specific 2020 outlook in January

10:11 EDT Kimberly-Clark: Q4 is toughest comp of the year, but sees 'solid' quarter

10:10 EDT JetBlue 'disappointed' in U.S./EU trade arguments, tariffs on Airbus aircraft - JetBlue management said they are "disappointed" in U.S./EU trade arguments and tariffs on Airbus aircraft. Management notes these tariffs will impact JetBlue and will result in higher fairs. Comments provided during Q3 earnings conference call.

10:04 EDT Sirius XM, Marvel announce multi-year podcast agreement - Sirius XM Holdings (SIRI) and Disney's (DIS) Marvel announced a multi-year agreement under which Marvel will create exclusive podcasts for SiriusXM and Pandora. "In Marvel's most sweeping podcast deal ever, the venture will include both scripted and unscripted series, themed live events, and much more, premiering in 2020," the company said in a statement. SiriusXM and Pandora will also debut Marvel's podcasts before they can be heard anywhere else. Included in the slate of upcoming programming are four new scripted series, each ten episodes, based around the characters of Wolverine, Hawkeye, Black Widow, and Star-Lord, as well as a fifth series in which all four team up.

10:01 EDT Jet Aviation, GE Aviation sign long-term fleet modernization agreement - Jet Aviation and GE Aviation have signed a long-term agreement for a comprehensive safety and fleet modernization project including C-FOQA. The program covers Jet Aviation's global fleet of some 300 aircraft including Airbus, Boeing BBJ, Bombardier, Dassault, Gulfstream and more. "The partnership with GE Aviation and their C-FOQA Flight Efficiency Services data analytics marks a continued commitment Jet Aviation has in the support of our flight operations, our flight crews and, most importantly, our customers," Don Haloburdo, vice president, Flight Services, Jet Aviation, said. "Because safety will always be our top priority, we've chosen to work with the industry leader."

10:00 EDT ServiceMaster falls -12.2% - ServiceMaster is down -12.2%, or -$6.87 to $49.27.

10:00 EDT Harley-Davidson rises 6.9% - Harley-Davidson is up 6.9%, or $2.54 to $39.62.

10:00 EDT Cision rises 18.0% - Cision is up 18.0%, or $1.52 to $9.97.

09:50 EDT KAR Auction adds three to board, including partner at JANA - KAR Auction Services announced earlier three additions to its board of directors, including Stefan Jacoby, David DiDomenico and Mary Ellen Smith. Before transitioning into his current advisory and mentorship roles focused on mobility and autonomous and electric vehicles, Jacoby was a member of the General Motors global leadership team as executive vice president at GM International operations in Singapore. For the past nine years, DiDomenico has been a partner at JANA Partners, where he previously served as a portfolio manager for funds focused on event-driven strategy. Smith has spent the past 13 years advancing her career through multiple leadership roles at Microsoft, where she is currently corporate vice president of worldwide business operations. Jim Hallett, chairman and CEO of KAR Global, said, "It only makes sense that we tap board talent with decades of experience in financial investments like David, with the automotive industry success that Stefan has achieved and with the deep global operations and technology expertise that Mary Ellen brings to the table. Our board of directors with diverse backgrounds and deep knowledge will help lead the KAR Global evolution into an even more data-driven, technology-enabled company."

09:48 EDT NextDecade Corporation trading halted, volatility trading pause

09:47 EDT ServiceMaster falls -10.4% - ServiceMaster is down -10.4%, or -$5.82 to $50.32.

09:47 EDT Harley-Davidson rises 8.2% - Harley-Davidson is up 8.2%, or $3.04 to $40.12.

09:47 EDT Cision rises 18.2% - Cision is up 18.2%, or $1.54 to $9.99.

09:37 EDT Harley-Davidson sees cost of $20M from China tariffs in FY20

09:31 EDT H&R Block names Jamil Khan as Chief Strategy & Development Officer - H&R Block announces that Jamil Khan will join the company as Chief Strategy & Development Officer effective October 28. In this role, Khan will report directly to President and CEO Jeff Jones, helping develop strategic initiatives, identify growth opportunities and generate value for all stakeholders. Most recently, Khan served as Senior Vice President of Strategy & Business Development for Cengage, a Boston-based technology company focused on disrupting the traditional textbook market.

09:29 EDT Cray awarded GBP48M contract to for Shasta supercomputer - Cray (CRAY), a Hewlett Packard Enterprise company (HPE), announced at a signing ceremony in London that UK Research and Innovation have awarded Cray a GBP48M contract award to expand its high-performance computing capabilities with Cray's next-generation Shasta supercomputer. The new ARCHER2 supercomputer will be the first Shasta system announced in EMEA and the second system worldwide used for academic research. ARCHER2 will be the UK's most powerful supercomputer and will be equipped with the revolutionary Slingshot interconnect, Cray ClusterStor high-performance storage, the Cray Shasta Software platform, and 2nd Gen AMD EPYC processors. The new supercomputer will be 11X higher performance than its predecessor, ARCHER.

09:26 EDT Alphatec announces commercial launch of titanium line of IdentiTi implants - Alphatec Holdings announced the commercial release of its porous titanium line of IdentiTi implants for lateral interbody fusion procedures. The launch of the IdentiTi LIF Interbody Implant Systems follows successful alpha evaluations that began in January 2019. The Company has successfully commercialized all of the six IdentiTi Implant Systems slated for release in 2019. The Company also announced the commercial release of the AMP Lateral Anti-Migration Plate, as well as the re-design and reconfiguration of its PEEK lateral interbody implant offering, Transcend. With the expected launch of SafeOp neuromonitoring next month, in November 2019, ATEC is on track to launch all 12 of its planned commercial launches for 2019, executing on its commitment to accelerate growth through clinical distinction.

09:24 EDT Velan Capital sends letter to Progenics stockholders - Velan Capital announced that it has sent a letter to Progenics stockholders outlining the "current Board's failure to represent the best interests of stockholders, as most recently illustrated by the Company's agreement to be acquired by Lantheus Medical Imaging". The letter also "highlights the Company's recent misleading statements around Velan's intentions" and urges stockholders to consent to the replacement of three of the company's decade-plus tenured directors with Velan's five fully-independent nominees. The letter said, "Velan Capital, L.P., together with the other participants (collectively, "Velan" or "we") in its call for changeat Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX), collectively beneficially own approximately 11.7% of the Company's outstanding shares, making us one of Progenics' largest stockholders. In fact, we have invested more than $35 million of our personal capital in the Company, while the Company's directors have themselves invested almost nothing in Progenics (despite having received tens of millions of dollars in compensation for their Board service). Unfortunately, the current Progenics Board of Directors (the "Board") continues to imperil the investments of its stockholders. Consider its strategic flip-flopping: as recently as this summer, the Board touted the purported potential of the Company's existing "strategic business plan" and proclaimed the Board and management team had "successfully mastered [AZEDRA's] extremely complex commercialization process" - statements made, in Velan's view, to avoid Board change at the Company's 2019 Annual Meeting. Now, under the threat of a consent solicitation, the Board has changed its tune and does not seem to believe there is significant value to be realized at Progenics, given its recent announcement of an agreement to be acquired by Lantheus Medical Imaging, Inc. ("Lantheus"). Perhaps, as we suspect, the directors may be putting personal preferences ahead of stockholders' best interests and seeking a more "graceful" exit. What's more, the Board has also resorted to spreading false and misleading rumors about one of its largest stockholders in what appears to be a desperate attempt to avoid accountability at all costs and sell the Company at a massive discount. Stockholders must ask themselves whether they trust the current Board to represent their best interests. In our view, the answer is clearly no. This Board has consistently failed stockholders, changed strategic course in service of its singular goal of entrenchment and has proven extremely reluctant to let the voices of stockholders be heard..."

09:23 EDT Boeing says making 'significant progress' on safely returning 737 MAX to service - Boeing announced that it has "made significant progress over the past several months in support of safely returning the 737 MAX to service as the company continues to work with the FAA and other global regulators on the process laid out for certifying the 737 MAX software and related training updates." "In addition to providing assistance to those affected by these accidents, teams from across Boeing and our supplier partners have been working around the clock to develop software updates and conduct related flight testing, enhance future pilot training materials, engage and inform global regulators, airline customers and our suppliers, and support the existing fleet of 737 MAX airplanes...We updated the Maneuvering Characteristics Augmentation Software (MCAS) on the MAX by adding three additional layers of protection that will prevent accidents like these from ever happening again. To date, we have conducted more than 800 test and production flights with the updated software, totaling more than 1,500 hours. The company is making steady progress on the second software update announced in June for additional flight control computer redundancy. Some 445 participants from more than 140 customers and regulators around the globe, including the FAA, have participated in simulator sessions to experience the proposed MCAS software update. Just last week the company successfully conducted a dry-run of a certification flight test," the company said. The company has also made significant governance and operational changes to further sharpen its focus, Boeing stated in a press release. "We continue to make steady progress in safely returning the 737 MAX to service. Our Boeing teams are unwavering in their commitment to our customers and our values, and the changes we're implementing now will further strengthen our approach to safety across our company and the aerospace community," said CEO Dennis Muilenburg.

09:19 EDT Domo announces partnership with Snowflake - Domo announced a partnership with Snowflake, the data warehouse built for the cloud, that enables joint customers the ability to go from insight to action in real-time with their data. Through a new native API integration and a go-to-market agreement, the partnership between the cloud companies will impact customers as they move more data to the cloud to leverage the flexibility, scalability and security it provides.

09:17 EDT United Technologies says CFO Akhil Johri is retiring - Says Neil Mitchill will serve as acting CFO. Says 2019 is shaping up to be a really good year. Says reduced headcount recently. Says fundamentals of commercial businesses remain strong. Says not panicking about Carrier. Says Carrier saw decent growth in China. Says Otis saw profit growth in Europe. Comments taken from Q3 earnings conference call.

09:16 EDT Verizon offers customers 12 months of Disney+ - Verizon (VZ) and The Walt Disney Company's (DIS) Direct-to-Consumer and International segment announced a wide-ranging agreement that will offer all Verizon wireless unlimited customers, new Fios Home Internet and 5G Home Internet customers 12 months of Disney+. Set to launch on November 12, Disney+ will be the dedicated streaming home for movies and shows from Disney, Pixar, Marvel, Star Wars, National Geographic, and more. The agreement will allow Verizon Wireless customers to stream Disney+. Eligible Verizon customers will have access to the highly anticipated streaming service where they can experience everything Disney+ has to offer: never-before-seen original programming including feature-length films, series, documentaries, and short-form content made exclusively for Disney+, along with unprecedented access to Disney's vast collection of films and television shows. In its first year alone, Disney+ will release more than 25 original series and 10 original films and documentaries, including "The Mandalorian," from executive producer and writer Jon Favreau, and "Lady and the Tramp," a timeless re-telling of the 1955 animated classic.

09:14 EDT MasterCard acquires SessionM, terms not disclosed - Mastercard announced it has entered into an agreement to acquire SessionM, a U.S.-based technology company. "The addition of SessionM will enhance Mastercard's ability to help brands around the world deliver personalized, real-time offers and comprehensive campaign measurement based on robust, data-driven insights. Mastercard is constantly innovating and investing to bring fresh value to brands globally-helping them build and enhance their customer relationships and, ultimately, grow their business." Terms of the agreement were not disclosed and the transaction is anticipated to close in Q4.

09:12 EDT Capstone Turbine says reaches record of 250MW under long-term FPP contracts - Capstone announced that it has reached a new record of 250 MW under long-term Factory Protection Plans service contracts. The FPP aftermarket product remains a key strategic initiative, and the company continues to sign new contracts as well as transitioning existing customers with a record of $4.2M in first-quarter FPP revenue. This is the third-highest aftermarket revenue quarter and the highest ever first-quarter aftermarket revenue in Capstone's history. Another key milestone was reached in the quarter with an FPP attachment rate of 38%, which is a record for the company and demonstrates it is well on the way to the stated near term target of 45%.

09:11 EDT Capstone Turbine sees lowering quarterly operating expenses to $5.2M-$5.7M - Capstone Turbine provided an update on its multiple strategic business initiatives and stated goal of achieving positive Adjusted EBITDA for the quarter ending June 30, 2020. Capstone Turbine had previously announced its goal of reaching positive Adjusted EBITDA by focusing on improving the business in areas that it has direct control of, and in areas that are not impacted by externalities such as project delays, macroeconomic conditions, geopolitical events, trade wars, etc. During the recent first-quarter earnings call, the company outlined a gross margin growth strategy that would produce an estimated $5.4M, or a 24% gross margin in the upcoming quarter ending June 30, 2020. Today, the company is announcing that it is executing effectively on its strategic business initiatives, and now expects the company can lower its average quarterly operating expenses to a range of $5.2M-$5.7M, including in the upcoming quarter ending June 30, 2020, which could potentially generate a positive Adjusted EBITDA result during the quarter.

09:09 EDT Jaguar Health says study shows Mytesi may support diarrhea treatment in cancer - Jaguar Health announced additional findings from the recently completed preclinical study evaluating the effects of Mytesi on diarrhea induced by a specific tyrosine kinase inhibitor. The study in healthy dogs was designed to reinforce a scientific rationale for the use of crofelemer when human patients undergo treatment with targeted cancer therapies including, but not limited to, TKIs with or without cycle chemotherapy. Specifically, the preclinical study showed that crofelemer treatment resulted in lesser incidence and severity of diarrhea with the maintenance and tolerability of a higher dose of the selected TKI. Funded by a third-party manufacturer of an FDA-approved TKI for human use, the study points to potential benefits that the Company hopes to see in future human studies of crofelemer's ability to provide symptomatic relief of noninfectious diarrhea in patients receiving a targeted cancer therapy in an adjuvant or metastatic setting. The results showed that the animals in the crofelemer groups received approximately 20% higher doses of the TKI than the animals in the placebo group through the four weeks of the treatment period. The TKI dose reductions over the four-week period were statistically higher for the control group compared to the crofelemer QID group and trending toward statistical significance in the BID group. In general, the treatment effect of crofelemer was 1.5 to 2.5 times better than placebo for multiple endpoints in this study.

09:08 EDT Biogen says 'just started' to contact European regulators about aducanumab - Biogen executives said the company has "just started" to contact European regulators about aducanumab and they have not yet had "substantive discussions" about the new analysis of a larger dataset from the Phase 3 clinical studies.

09:05 EDT Trillium Therapeutics says ongoing dose escalation trial of TTI-621 'on track' - The company said, "The ongoing dose escalation trial of intravenously administered TTI-621 is on track and remains the key strategic priority going forward. The 0.7 mg/kg dose cohort in this study has been completed and no dose-limiting toxicities have been identified. Enrollment in the 1.0 mg/kg cohort is beginning. The goal of this trial is to identify a recommended phase 2 dose to enable additional studies in both cutaneous T-cell lymphoma and other hematologic malignancy indications with high unmet medical need. In September, the company met with the U.S. Food and Drug Administration which provided guidance on the intratumoral use of TTI-621 for the treatment of early-stage CTCL, including aspects of a potential registration study. The company is evaluating this guidance and considering options going forward, given current resource constraints. The ongoing phase 1b intratumoral trial, which provided the data set for the FDA interaction and informed the guidance, will now be closed."

09:04 EDT Trillium Therapeutics to discontinue discovery research activities

09:04 EDT Trillium Therapeutics ro reduce staff by 40% in corporate restructuring - Trillium Therapeutics announced corporate restructuring to extend the company's cash runway and to focus on critical value-creating activities. The company also provided an update on its clinical development and research programs. "Since assuming the CEO role a month ago, my immediate focus has been on conducting an in-depth review of our strategic priorities and ongoing programs, as well as our available resources," said Jan Skvarka, President and CEO. "Building on our strong scientific foundation, the goal of this restructuring is to create a leaner, more clinical development-centric organization and extend our cash runway. The near-term focus will be on the clinical development of intravenously administered TTI-621, our anti-CD47 product candidate that has shown promising preliminary evidence of activity in a number of hematologic malignancies. Unfortunately the restructuring will impact many highly talented and dedicated employees. Trillium would not exist without their contributions, for which we will always be deeply grateful." Under the restructuring program, staff will be reduced by 40%, from 43 to 26 active employees, with immediate effect. The company will discontinue its discovery research activities to focus on clinical development and seek a partner for further development of its preclinical STING agonist program. Further cost savings will be achieved through operational efficiencies. These savings are expected to reduce cash outlay from approximately C$10M per quarter in the first half of 2019 to approximately C$4-7M per quarter in 2020. The company currently expects to have cash and cash equivalents of approximately C$36M at the end of the third quarter of 2019.

08:59 EDT Fly Intel: Pre-market Movers - HIGHER: Biogen (BIIB), up 37% after announcing it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. Phase 3 clinical studies for aducanumab previously had been discontinued in March 2019 following a futility analysis... Under Armour (UAA), up 2% after announcing Kevin Plank will step down as CEO and will be replaced by Patrik Frisk. Plank will become executive chairman & brand chief... Stamps.com (STMP), up 18% after entering a logistics services deal with UPS (UPS). UP AFTER EARNINGS: Procter & Gamble (PG), up 4%... United Technologies (UTX), up 2%... Harley-Davidson (HOG), up 6%... Polaris Industries (PII), up 3%. DOWN AFTER EARNINGS: UPS (UPS), down 3%... Travelers (TRV), down 4%... Hasbro (HAS), down 14%... ALSO LOWER: Tile Shop (TTS), down 67% after suspending dividend, cancelling share repurchase plan and announcing plan to delist from Nasdaq... Pareteum (TEUM), down 47% after announcing the company will restate its previously issued consolidated financial statements as of and for the full year ended December 31, 2018, and interim periods ended March 31 and June 30.

08:55 EDT CV Sciences appoints Paul Blake to board of directors - CV Sciences (CVSI) announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019. He currently serves as CMO at Heron Therapeutics (HRTX).

08:54 EDT P&G says facing challenges from 'volatile' macro, geopolitical environment

08:52 EDT Raven Industries awarded contracts for persistent surveillance systems - Raven Industries announced that Raven Aerostar Technical Solutions was awarded a $5.7M contract to deliver TIF-25K Aerostat Systems sparing hardware to six existing aerostat sites in Afghanistan. Raven Aerostar Technical Solutions was also awarded a $4.7M contract to deliver two TIF-25K Aerostat Systems and associated sparing hardware in support of two additional aerostat sites in Afghanistan. Both contracts will be delivered within the next 12 months.

08:46 EDT ElectraMeccanica appoints Peter Savagian to board of directors - ElectraMeccanica Vehicles Corporation announced that the Board of Directors has appointed Peter Savagian as an Independent Director, effective immediately. Savagian is presently SVP of Engineering at Ampaire, an electric aircraft startup company where he directs innovation, design, development and certification of electric propulsion systems and their integration into short-haul, fixed-wing electric aircrafts.

08:44 EDT Procter & Gamble says productivity continues to be a significant focus area

08:43 EDT Cision to be acquired by Platinum Equity affiliate in deal valued at $2.74B

08:41 EDT Procter & Gamble boosts FY20 adj. free cash flow productivity view to 95% - Previous view was 90%.

08:39 EDT Covetrus CEO Benjamin Shaw steps down, Benjamin Wolin named acting CEO - Covetrus announced that Benjamin Shaw has stepped down as the company's president and CEO and will transition to a strategic advisor to the board. Benjamin Wolin, who currently serves as the company's chair of the board, will assume the role of acting CEO and president. Philip Laskawy, the board's lead independent director, will take over as board chair. Wolin has experience with public company leadership, as well as financial and operating expertise. Previously, he was the CEO and co-founder of Everyday Health, a communications and marketing platform for consumers, doctors and healthcare companies, and a member of its board of directors for 14 years.

08:35 EDT CVD Equipment announces Q3 new orders of $7.9M - CVD Equipment announced that it has received approximately $7.9M in new orders during Q3 as compared to new orders of approximately $6.5M and $3.3M in Q1 and Q2, respectively. The new orders will be delivered over the next several quarters.

08:33 EDT Heron Therapeutics receives approval from FDA for Cinvanti's sNDA - Heron Therapeutics announced that the FDA has approved Heron's supplemental New Drug Application, or sNDA, for CINVANTI, or aprepitant, injectable emulsion for intravenous, or IV, use. The sNDA requested FDA approval to expand the recommended dosage to include the 130 mg single-dose regimen for patients receiving MEC. CINVANTI is the first and only IV formulation of a substance P/neurokinin-1 receptor antagonist that is free of synthetic surfactants, including polysorbate 80, and that is approved for use as a 2-minute IV injection.

08:27 EDT Atlantic Union Bankshares announces new equipment finance division - Atlantic Union Bank announced a new division of the Bank called Atlantic Union Equipment Finance. Atlantic Union Equipment Finance will provide a wide variety of equipment finance solutions to commercial and corporate customers. This includes providing financing for equipment assets including marine, tractors, trailers, buses, construction, manufacturing and medical, among other types of equipment. Atlantic Union Bank will leverage this new capability to take advantage of opportunities across its Mid-Atlantic footprint, in addition to financing outside the Mid-Atlantic. Jule Kreyling will serve as President of Atlantic Union Equipment Finance and will report to David Ring.

08:24 EDT RigNet opens new office in Lafayette, Louisiana metropolitan area - RigNet announced that it has completed the consolidation of four offices in the Lafayette area into a single new facility. This new office will accommodate RigNet's growing customer base and support its Gulf of Mexico operations including RigNet's new 4G LTE and 5G-capable network launched across more than 60,000 square miles of the Gulf of Mexico. This network now connects offshore workers, vessels and critical infrastructure in an area larger than the state of Florida. Local employees of recently acquired DTS, Autocomm and SAFCON will join RigNet's employees at this new office. The new facility is over 55,000 square feet of office and warehouse space and is RigNet's largest operational facility supporting all key functions for managed services with approximately 130 staff members based there. This location also includes a fabrication shop for RigNet's in-house fabrication as well as a dedicated area for customer factory acceptance testing for large scale projects.

08:20 EDT IntelGenx announces FDA acceptance of resubmitted RIZAPORT NDA - IntelGenx announced that its 505(b)(2) New Drug Application for RIZAPORT VersaFilm for the treatment of acute migraines has been accepted for review by the U.S. Food and Drug Administration. The FDA has assigned a Prescription Drug User Fee Act goal date for completion of the review of the RIZAPORT NDA of March 26, 2020.

08:18 EDT Splunk closes funding in Zonehaven - Splunk announced that the company has closed funding in Zonehaven, a cloud-based analytics application designed to help communities improve evacuations and reduce wildfire risk with data. The funding is the first investment from Splunk's newly launched Splunk Ventures Social Impact Fund, a $50M fund that invests in early stage organizations that are using data driven approaches to drive social impact. Launched in 2018, Zonehaven gives fire departments and emergency response agencies unprecedented situational awareness and decision support by utilizing intelligent evacuation zones, advanced fire modeling, real-time weather data and always-on fire sensing capabilities.

08:15 EDT CytoSorbents awarded $3M contract by U.S. Air force Materiel Command - CytoSorbents announced that the U.S. Air Force Materiel Command has awarded the Company a two-year contract valued at up to $2,959,747 as part of the Rapid Innovation Fund, or RIF, to advance its program, entitled "K+ontrol Renal Support System for Reduction of Hyperkalemia," towards a U.S. clinical trial designed to support FDA regulatory approval. Severe hyperkalemia, or dangerously high potassium levels in the blood, is a serious complication of trauma, crush injury, and prolonged limb ischemia. It is particularly relevant in military trauma, afflicting approximately 6% of U.S. combat casualties in the wars in Iraq and Afghanistan.

08:12 EDT Pros Holdings announces John Allessio as chief customer officer - Pros Holdings (PRO) announced that John Allessio, an expert at building successful customer implementation and adoption programs, has joined the company as chief customer officer, a new role intended to deepen customer engagement and further support the company's global growth plans. Serving in global leadership roles at Red Hat and IBM (IBM), Allessio brings more than 30 years of customer success, support and enablement experience to Pros. In this role, Allessio reports directly to Andres Reiner, Pros president and CEO, and is responsible for driving end-to-end customer experience, increasing user adoption of PROS solutions and powering partner enablement to drive growth across the company.

08:10 EDT NetSol's NFS Ascent Wholesale Platform goes live in China for auto captive - NETSOL Technologies has implemented and gone live with its NFS Ascent Wholesale Platform for a tier-one German auto captive finance company in China. This customer has a strong presence in China as well as the rest of the Asia-Pacific region. This deployment is part of a previously announced $30M contract in which NETSOL was selected as the vendor of choice after an extensive evaluation process. NFS Ascent's Wholesale Finance Solution was chosen for its specific applications directed to the Chinese market as well as its compliance with various regulations set out by the People's Bank of China and other industry governing bodies.

08:07 EDT Kaleido, Washington University School of Medicine announce collaboration - Kaleido Biosciences has entered into a research collaboration with Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology at Washington University School of Medicine, to explore the influence of Microbiome Metabolic Therapies on microbial and host physiology and metabolism. Under the collaboration, gnotobiotic preclinical models will be combined with innovative experimental and computational methods to further identify molecular pathways by which Kaleido's MMTs can modify the functional configuration of the gut microbiome and its metabolic outputs.

08:06 EDT AzurRx BioPharma CEO says 'on track' to meet with FDA in December - AzurRx BioPharma issued a letter to its shareholders and the investment community from its newly appointed CEO, James Sapirstein. The letter read, in part, "It is with great pleasure that I am writing to you as the new President and Chief Executive Officer of AzurRx BioPharma. I am very excited to join the AzurRx team as we advance MS1819 and our product pipeline towards their next milestones. I joined AzurRx because I firmly believe in the clinical and commercial potential of MS1819 and see that there is a clear path to the market. Additionally, I was drawn by the support of the seasoned management and world-class clinical teams...In the past week, AzurRx has made two major positive announcements. Early last week we announced that the first patients were dosed in our Phase 2 combination therapy study for cystic fibrosis patients with severe exocrine insufficiency. This has significance for the one-third of CF patients whose nutritional needs cannot be met with porcine enzymes alone. Our second announcement was that the Cystic Fibrosis Foundation Data Safety Monitoring Board, which reviewed our Phase 2 OPTION study results, concluded that MS1819 is safe and supported our plan to proceed to a higher 4-gram dose of MS1819 in the next Phase 2 replacement therapy clinical trial. The DSMB's support will bolster our investigational new drug application with the FDA and enable us to continue working with Cystic Fibrosis Foundation-supported clinical sites and investigators. Looking forward, we are on track to meet with the FDA in December and to initiate the Phase 2 4-gram study in Q1 2020. Based on our experience with the OPTION study, we anticipate rapid enrollment, completion, and topline data read-out before the end of 2020. In addition, we anticipate an initial read-out from the combination therapy study by mid-year 2020. I would like to ensure our investors that the entire management team and I are focused on building shareholder value and on executing upon our milestones. We firmly believe in the potential for MS1819 and are committed to moving forward in development, including ensuring that we have the capital to execute on our plans. We believe shareholders will be rewarded as we execute on our strategy."

08:04 EDT InVivo Therapeutics announces INSPIRE 2.0 study at 25% enrollment - InVivo Therapeutics announced that a total of five patients have been enrolled into the INSPIRE 2.0 Study, bringing the study to 25% completion of targeted enrollment. The first patient was enrolled into the INSPIRE 2.0 Study in May and 14 sites are currently open for enrollment into the study.

08:03 EDT McDonald's announces 8% increase in quarterly dividend to $1.25 per share - The company announced an 8% increase in its quarterly dividend to $1.25 per share beginning in the third quarter.

08:02 EDT McDonald's reports Q3 systemwide sales up 5% to $26B - Systemwide sales increased $1.3B or 5% (7% in constant currencies) to $26B.

08:00 EDT McDonald's reports Q3 U.S. SSS increased 4.8%

07:57 EDT Michaels appoints Mark Cosby as CEO - Michaels announced that Mark Cosby has been named CEO effective immediately. Cosby has served as Interim CEO and a member of the board since February. The appointment of Cosby follows a comprehensive search process conducted by a special committee of the Board.

07:48 EDT EQT Midstream Partners-owned MVP says project work will be 90% complete by 2020 - Mountain Valley announced total project work will be approximately 90% complete by year-end 2019, with an adjusted in-service date of late 2020 and revised total cost estimate of $5.3B-$5.5B. Notwithstanding various legal and regulatory challenges during 2019, the Mountain Valley Pipeline, or MVP, project team was able to make significant construction progress. MVP's three compressor stations and three certificated interconnects are now 100% complete; approximately 80% of the pipeline work is complete, which includes 264 miles of pipe welded and in place; and approximately 50% of the right-of-way has been fully restored. On October 15, the Federal Energy Regulatory Commission, or FERC, issued a project-wide order halting forward-construction progress in response to the U.S. Fourth Circuit Court of Appeals order granting a stay of MVP's biological opinion and incidental take statement issued by the U.S. Fish and Wildlife Service in November 2017. Much of MVP's forward-construction work was already deferred in accordance with MVP's August voluntary suspension or had been largely winding down for the winter season. The FERC's order directs MVP to focus on restoration and stabilization activities to protect the environment, which has been a primary focus of the MVP team in its preparation for winter, including enhancing erosion and sediment controls and continuing with restoration work. MVP's late 2020 in-service date and cost adjustment reflects changes to the previously planned construction schedule. The project's voluntary suspension of forward-construction and inability to work in streams and wetlands prevented Mountain Valley from fully completing portions of the route and shifted more mainline work into 2020. This resequencing of work has created carrying costs and caused the use of additional time and crews needed to safely maintain the entire 303-mile route over the winter, as opposed to focusing on maintaining only unrestored sections of the route had construction been fully completed as planned during 2019.

07:45 EDT Moleculin Biotech raises Annamycin production - Moleculin Biotech announced the expansion of Annamycin production commitments in response to management's assessment of positive AML clinical trial activity and the potential expansion of indications for use to include lung-localized tumors. The purchase commitment arranged through Davos Pharmaceuticals includes moving final production of Annamycin to a larger-scale suite within BSP Pharmaceuticals S.p.A. in Latina, Italy. Until now, BSP has been producing the clinical supplies of Annamycin in a smaller pilot-scale suite. Dr. Donald Picker, Moleculin's Chief Science Officer added: "With management's view of success in clinic and the expectation of wider demand resulting from additional clinical trials in lung-localized tumors, it's time for Moleculin to start preparing for an eventual drug approval process. That requires the development and validation of commercial scale methods and this move with BSP marks the beginning of that process. In addition to increasing the scale of clinical supply production, we will be working with BSP and with our manufacturer of API to develop the commercial scale synthesis and drug production methods we will need to ultimately prepare for New Drug Approval."

07:40 EDT Callon Petroleum files presentation highlighting benefits of Carrizo deal - Callon Petroleum Company (CPE) announced that it has filed an investor presentation with the SEC in connection with its previously announced pending all-stock acquisition of Carrizo Oil & Gas (CRZO). Reference Link

07:38 EDT Lockheed Martin sees FY20 sales $62.0B, consensus $62.82B - The company said "The corporation expects its 2020 net sales to increase to approximately $62.B. Total business segment operating margin in 2020 is expected to be in the 10.5%-10.8% range and cash from operations is expected to be greater than or equal to $7.2B, net of $500M of pension contributions. The preliminary outlook for 2020 assumes there is no impact from U.S. Government actions related to Turkey and the U.S. Government continues to support and fund the corporation's key programs. Changes in circumstances may require the corporation to revise its assumptions, which could materially change the corporation's current estimate of 2020 net sales, operating margin and cash flows. The corporation currently expects a total net FAS/CAS pension benefit of approximately $2.1B in 2020. This estimate assumes a 3.25% discount rate, a 15.00% return on plan assets in 2019, and a 7.00% expected long-term rate of return on plan assets in future years, among other assumptions. A change of plus or minus 25 basis points to the assumed discount rate, with all other assumptions held constant, would result in an incremental increase or decrease of approximately $15M to the estimated net 2020 FAS/CAS pension benefit. The impact of changes in the discount rate is significantly less than in prior years due to the expected completion of the planned freeze of the corporation's salaried pension plans."

07:34 EDT Kimberly-Clark provides update to 2018 Global Restructuring Program - The company said, "In January 2018, Kimberly-Clark initiated the 2018 Global Restructuring Program in order to reduce the company's structural cost base and enhance the company's flexibility to invest in its brands, growth initiatives and capabilities critical to delivering future growth. The company expects the program will generate annual pre-tax cost savings of $500 to $550 million by the end of 2021. As part of the program, Kimberly-Clark expects to exit or divest some low-margin businesses that generate approximately 1 percent of company net sales. To implement the program, the company expects to incur restructuring charges of $1,700 to $1,900 million pre-tax ($1,350 to $1,500 million after tax) by the end of 2020. Through the third quarter of 2019, the company has incurred cumulative restructuring charges of $1,251 million pre-tax ($964 million after tax) and generated cumulative savings of $260 million."

07:34 EDT Radient Technologies, Edlong Corporation enter MOU to form strategic JV - Radient Technologies and The Edlong Corporation announced they have entered into a Memorandum of Understanding to form a strategic Joint Venture partnership. The purpose of the JV is for the two companies to jointly create and market cannabidiol flavor systems and product solutions for global food, beverage, and pet food industries. Combining Edlong's expertise in the development, manufacturing and marketing of natural flavors and ingredients with Radient's expertise in the industrial-scale extraction, purification and manufacturing of cannabinoid ingredients, the two companies will collaborate on the development of high-quality, CBD-based flavors and ingredients that will meet global health and safety regulations and appeal to large global consumer markets. Additional areas of interest for collaboration may be included in the future, should the two companies agree to pursue them.

07:30 EDT Delcath Systems announces postponement of reverse stock split - Delcath Systems announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent notification received from FINRA after-market that they have decided to continue their review.

07:26 EDT ForeScout joins global cyber security alliance for operational technology - Forescout Technologiesy announced that it has joined a new alliance to provide a technical and organizational framework for safe and secure operational technology. The Operational Technology Cyber Security Alliance aims to bridge dangerous gaps in security for OT and critical infrastructures and industrial control systems to support and improve the daily lives of citizens and workers in an evolving world. Industry leaders ABB, Check Point Software, Cylance, Fortinet, Microsoft, Mocana, NCC Group, Qualys, SCADAFence, Splunk and Wartsila have partnered with Forescout to establish the OTCSA.

07:22 EDT Orchard Therapeutics 'on track' to submit MAA for MLD in 1H20 - Orchard remains on track to submit a marketing authorization application in Europe for MLD in the first half of 2020, as well as a biologics licensing application in the U.S. approximately one year later.

07:18 EDT Neovasc announces multiple presentations featuring Neovasc Reducer - Neovasc announced that the Neovasc Reducer was featured in multiple presentations during the symposium "A Proven Evidence-based therapy when Angina Persists", held this month at the National Congress of the Italian Society of Interventional Cardiology in Milan, Italy. The highlights showed that 50% of the patients improved by 2 CCS Classes or more while 83% of patients improved by 1 CCS Class or more. Seventeen percent did not respond to the therapy. Additionally, the average CCS score decreased from 3.2 to 1.7. In selected presentations: Prof Shmuel Banai, Director, Division of Cardiology Tel-Aviv Medical Center, and Neovasc Medical Director, presented the history and rationale of coronary sinus narrowing for the treatment of angina. In 1948, American Cardiac Surgeon, Claude Schaffer Beck, developed an effective treatment for patients with disabling angina by creating a surgical narrowing of the coronary sinus. Between the years 1948 to 1964 Dr. Beck successfully used this procedure on more than 1,000 patients with coronary heart disease. In 1952, Dr. Beck became the first to receive the title of professor of cardiovascular surgery in the United States. More recently, Neovasc developed non-surgical methods to narrow the coronary sinus in Europe and Canada. These methods proved effective, enhancing blood supply to the ischemic heart, increasing quality of life and protecting the heart while reducing infarct size. Pr. Sergio Berti, Fondazione Toscana G. Monasterio, based on recent survey data of clinical cardiologists in the Milan area, reinforced that many patients suffer from angina despite optimal therapy. The clinical cardiologists polled estimate that as many as 12% of their angina patients are refractory to currently available therapies. On average, these physicians each had 20 such patients, of which approximately 50% were not satisfied with their current therapy. Physicians confirmed they would likely have sent these patients for a definitive interventional treatment, if they were aware of such a therapy. The conclusion of the survey was that there are still many patients with refractory angina, who are not satisfied with their quality of life or their current therapy, and who could potentially benefit from the Reducer. These leading cardiologists reinforced that the suffering of patients has a significant impact on their everyday life. As a measure of that, these patients on average return for a consultation on a monthly basis. Dr. Francesco Giannini, GVM Care & Research Maria Cecilia Hospital - Cotignola, reviewed the technical and procedural aspect of the Reducer Therapy. During his presentation, Dr. Giannini reinforced the strong safety profile of the procedure. On behalf of the investigators, Dr. Gianpiero D'Amico, University of Padua, presented the Italian Society of Interventional Cardiology Multi-Center study on the "Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina." One hundred eighty three patients suffering from severe refractory angina were treated with coronary sinus narrowing by Reducer implantation in 16 medical centers across Italy. Presented data demonstrated a 98% technical success rate. Efficacy data at median follow-up of 564 days showed significant improvements in angina severity with minimal rates of complications. Results, based on the Canadian Cardiovascular Society Class, showed that 50% of the patients improved by 2 CCS Classes or more, 83% of patients improved by 1 CCS Class or more and 17% did not respond to the therapy. The average CCS score decreased from 3.2 to 1.7. Quality of life as assessed by the Seattle Angina Questionnaire also improved significantly across all 5 domains. Data comparing the CCS Class improvement results of the Italian registry to seven other previously published Reducer studies demonstrated consistent results across all studies. Finally, the current President of GISE, Pr. Giuseppe Tarantini, University of Padua, reinforced the importance of the new European Society of Cardiology guidelines for the Reducer Therapy and the importance of this therapy for patients who currently have few treatment options

07:16 EDT Quarterhill names David Cortens as interim CFO, succeeding Shaun McEwan - Quarterhill announced that the company's Board of Directors has appointed David Cortens, currently CFO at International Road Dynamics, as Quarterhill's interim Chief Financial Officer, effective immediately. Shaun McEwan, Quarterhill's outgoing CFO, will remain with the company until the end of 2019 to effect a smooth transition. Cortens is a Chartered Professional Accountant with more than 35 years of experience in finance-related roles with public and private companies. Prior to this announcement he has been the CFO at IRD, a position he has held since 2012.

07:14 EDT Eton Pharmaceuticals announces FDA approval of Biorphen injection - Eton Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Biorphen, a ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

07:10 EDT Procter & Gamble: Q1 operating profit margin increased 280 basis points - Operating profit margin increased 280 basis points versus the base period on a reported basis including approximately 20 basis points help from lower non-core restructuring charges. Core and currency-neutral operating margin increased 260 basis points including total productivity cost savings of 160 basis points for the quarter. Foreign exchange was neutral to operating margin for the quarter.

07:09 EDT Veracyte announces preliminary nasal swab test clinical data - Veracyte announced preliminary clinical data showing that the company's noninvasive nasal swab test can enable early lung cancer detection and diagnosis. The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The findings will be presented at the annual meeting of the American College of Chest Physicians. To develop and evaluate the test, Veracyte utilized nasal samples from over 700 patients with lung nodules found on computed tomography, or CT, scans who were prospectively recruited and whose cancer status was subsequently determined. The researchers evaluated the test's performance on an independent blinded subset of 261 patients. The researchers determined the genomic test's ability to identify patients as high risk and low risk for cancer and then modeled its impact on patient care when the cancer prevalence is 25%. This aligns with the anticipated cancer prevalence among the people on whom the test will eventually be used. Among patients whose nodules were benign, the genomic test classified over 40% as low risk for cancer, with a sensitivity of over 95%, meaning that these patients could be monitored noninvasively with a low chance of missing a cancer. Among patients whose nodules were malignant, the test classified over 40% as high risk for cancer, with a specificity of over 94%, meaning these patients could be directed to more invasive diagnostic procedures and treatment, with a low rate of false positive results. The test's performance was consistent regardless of lung nodule size or location, as well as cancer subtype or stage. Currently, physicians use clinical factors to calculate the risk of cancer when a lung nodule is found. However, these calculators vary widely in how they measure risk, produce differing results and have in some cases been shown to be less accurate than physician judgment alone. Researchers in the current study determined that the nasal swab test would identify over 70% more patients as "low risk" and 18% more patients as "high risk," as compared to one of the most widely used clinical risk calculators.

07:07 EDT Canadian Solar awarded 30 MWp project in Japan - Canadian Solar announced that it has been awarded a 30 MWp project in Japan's 4th solar energy auction. The project is located in Maniwa City within Okayama prefecture and will be powered by high-efficiency Canadian Solar modules. Once constructed, the project will enter into a 20-year power purchase agreement with Chugoku Power Electric Company at a rate of 12c, per kWh. The Company expects the project to reach commercial operation by 2024.In addition to the 30 MWp won in Maniwa City, the Company recently acquired five utility-scale solar power projects totaling 20.5 MWp that have secured feed-in-tariff contracts and are expected to reach commercial operation in the 2020-21 time frame.

07:06 EDT AerCap delivers new Boeing 787-9 Dreamliner to Air New Zealand - AerCap Holdings (AER) has announced the delivery of a new Boeing (BA) 787-9 Dreamliner on long-term operating lease to Air New Zealand. This is the first new 787-9 aircraft to deliver to Air New Zealand from AerCap's order book with Boeing. AerCap is the world's largest lessor of the Boeing 787 Dreamliner, with 117 aircraft owned, managed and on order.

07:05 EDT UPS sees FY19 adjusted free cash flow over $4B - "UPS delivered solid performance for the third quarter," said CFO Brian Newman. "Positive impacts from our transformation initiatives are visible in our results as we continue to improve network efficiencies and create new solutions that will open more growth opportunities well into the future." Adjusted free cash flow for the year is projected to be over $4B. Capital investments have been reduced in both 2019 and 2020 by about $500M each year. Network automation targets and other transformation goals remain unchanged. The effective tax rate for the full year 2019 is estimated to be between 22% and 23%.

07:04 EDT Asbury Automotive reports Q3 same store results - Q3 same store: Total revenue increased 2%; gross profit increased 3%; Gross margin increased 20 basis points to 16.0%; New vehicle revenue decreased 3%; gross profit decreased 12%; Used vehicle retail revenue increased 9%; gross profit decreased 1%; Finance and insurance revenue and gross profit increased 8%; Parts and service revenue increased 8%; gross profit increased 7%.

07:02 EDT Biogen preparing to launch Vumerity for multiple sclerosis - Biogen (BIIB) said in its earnings release, "We are preparing for the expected launch of Vumerity, which we believe will be an important addition to our market-leading multiple sclerosis portfolio." The company added, "In October 2019 the U.S. Food and Drug Administration issued a tentative approval for Vumerity, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of MS. Additionally, in July 2019 Biogen and Alkermes plc announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of Vumerity for relapsing-remitting MS, compared to Tecfidera. Vumerity was statistically superior to Tecfidera on the study's pre-specified primary endpoint, with patients treated with Vumerity self-reporting significantly fewer days of key gastrointestinal symptoms with intensity scores greater than or equal to 2 on the Individual Gastrointestinal Symptom and Impact Scale, as compared to Tecfidera." Vumerity is being developed by Biogen in collaboration with Alkermes (ALKS).

07:01 EDT Travelers reports Q3 adjusted book value $90.09, up 3% from last year - Reports Q3 underlying combined ratio 94.1% vs. 93.0% last year.

07:00 EDT Bristol-Myers: CheckMate -9LA Phase 3 trial met primary endpoint - Bristol-Myers Squibb announced that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer, met its primary endpoint of superior overall survival at a pre-specified interim analysis. The comparator in this study was chemotherapy alone for up to four cycles followed by optional maintenance therapy. The safety profile of Opdivo plus low-dose Yervoy and two cycles of chemotherapy in CheckMate -9LA was reflective of the known safety profiles of the immunotherapy and chemotherapy components in first-line NSCLC.

06:58 EDT Procter & Gamble CEO says 'we delivered strong top-line growth' in Q1 - "We delivered strong top-line growth, profit margin expansion and cash productivity in the first quarter, enabling us to increase our outlook for fiscal year results," said David Taylor, Chairman, President and CEO. "We will continue executing our strategies of superiority, productivity, constructive disruption and improving P&G's organization and culture to deliver balanced top-line and bottom-line growth along with strong cash generation in a challenging competitive and macroeconomic environment."

06:56 EDT Harley-Davidson backs FY19 motorcycle shipments view of 212,000-217,000 - For the full year 2019, the company continues to expect motorcycle shipments to be approximately 212,000 to 217,000. In the fourth quarter, the company expects to ship approximately 38,500 to 43,500 motorcycles. Motorcycles segment operating margin as a percent of revenue to be approximately 6 to 7 percent for FY19. Sees FY19 fFnancial Services segment operating income to be down year-over-year. Additionally, the company now expects capital expenditures of $205M-$225M, including approximately $20M to support manufacturing optimization, which is $20M less than prior quarter guidance .

06:55 EDT Under Armour appoints COO Patrik Frisk as CEO, effective Jan. 1

06:54 EDT Biogen reports Q3 MS revenues up 2% to $2.348B - Multiple sclerosis revenues, including $188 million in royalties on the sales of OCREVUS, increased 2% versus the prior year to $2,348 million. o Revenue growth was driven in part by the continued global launch of SPINRAZA, which contributed $547 million in revenues in the third quarter of 2019 compared to $468 million in the third quarter of 2018. Revenue growth was also driven by biosimilars revenues, which increased to $184 million compared to $135 million in the third quarter of 2018, primarily driven by IMRALDI. "Biogen delivered solid performance in the third quarter driven by continued resilience from our MS core business and growth from SPINRAZA and biosimilars," said Michel Vounatsos, Biogen's CEO. "SPINRAZA continued on a strongtrajectory, particularly outside the U.S., and we are preparing for the expected launch of VUMERITY, which we believe will be an important addition to our market-leading multiple sclerosis portfolio. In addition to the recent news on aducanumab, we made strong progress in our pipeline as we initiated new clinical programs targeting Parkinson's disease and brain contusion, and we look forward to nine important data readouts by the end of next year. We continue to believe that our core focus on neuroscience will lead to new innovative treatments for patients and will maximize long-term returns for our shareholders."

06:44 EDT Biogen soars 20% on plans to pursue Alzheimer's approval after FDA talks - Shares of Biogen are soaring after the company announced that, after consulting with the FDA, it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. "The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis. This new analysis of a larger dataset that includes additional data that became available after the pre-specified futility analysis shows that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB). In both studies, the safety and tolerability profile of aducanumab was consistent with prior studies of aducanumab," The company plans to file a Biologics License Application in early 2020 and will continue dialogue with regulatory authorities in international markets including Europe and Japan. Shares of Biogen are up 21% in premarket trading, or $46.49, to $270.00.

06:39 EDT Arch Coal backs FY19 total sales volume view 86.7- 92.1 tons - "We are confident in our well-defined strategy for long-term value creation and growth, and we are pursuing it aggressively," Eaves said. "We expect several major drivers to elevate shareholder value in coming quarters regardless of market conditions. These drivers include the build-out of our world-class Leer South mine; the transition of our flagship Leer mine into the heart of its reserve base; the completion of our highly synergistic joint venture with Peabody; and the continuation of our capital return program. Coupled with continued, strong operational execution, these drivers should enhance our already strong competitive position in coking coal markets, increase our cash-generating capabilities significantly, and translate into greater value for our shareholders."

06:37 EDT Ares Management sells ownership in Meade Pipeline to NextEra Energy Partners - Ares Management (ARES) announced that a fund managed by its Infrastructure and Power strategy has signed a definitive agreement to sell its 22.5% ownership interest in Meade Pipeline to a subsidiary of NextEra Energy Partner (NEP) for approximately $286M. Meade owns approximately 39% of the Central Penn Line, a FERC-regulated, 185-mile pipeline that originates in Susquehanna County, Pennsylvania, and extends to Lancaster County, Pennsylvania. Central Penn is the greenfield part of the larger Atlantic Sunrise project operated by The Williams Companies through Transcontinental Gas Pipe Line Company. The pipeline became operational in October 2018, and, through interconnection with the larger Transco pipeline system, it has the capacity to deliver up to approximately 1.7B cubic feet per day of natural gas from the northeastern Marcellus-producing area to markets in the mid-Atlantic and Southeastern regions of the United States. Included in the transaction is a future expansion opportunity that is expected to add an estimated 0.6B cubic feet per day of natural gas capacity to Central Penn through the addition of compression at new and existing stations. The transaction is expected to close in the fourth quarter, subject to closing conditions and regulatory approvals.

06:36 EDT Biogen to offer access to aducanumab to patients enrolled in Phase 3 studies

06:35 EDT Biogen plans aducanumab BLA in early 2020 based on FDA talks - Biogen (BIIB) and Eisai (ESALY) announced that, after consulting with the U.S. Food and Drug Administration, Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. The Phase 3 EMERGE Study met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients in the Phase 3 ENGAGE Study who received sufficient exposure to high dose aducanumab support the findings from EMERGE. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language. Patients also experienced benefits on activities of daily living including conducting personal finances, performing household chores such as cleaning, shopping, and doing laundry, and independently traveling out of the home. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer's disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes. The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis. This new analysis of a larger dataset that includes additional data that became available after the pre-specified futility analysis shows that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes. In both studies, the safety and tolerability profile of aducanumab was consistent with prior studies of aducanumab. Based on discussions with the FDA, the company plans to file a Biologics License Application in early 2020 and will continue dialogue with regulatory authorities in international markets including Europe and Japan. The BLA submission will include data from the Phase 1/1b studies as well as the complete set of data from the Phase 3 studies. The company aims to offer access to aducanumab to eligible patients previously enrolled in the Phase 3 studies, the long-term extension study for the Phase 1b PRIME study, and the EVOLVE safety study. Biogen will work towards this goal with regulatory authorities and principal investigators with a sense of urgency.

06:32 EDT PulteGroup reports Q3 unit backlog up 4% to 11,638 Homes - Reports Q3 backlog value up 2% to $5.0B.

06:27 EDT AAC Holdings expects agreement securing additional liquidity - AAC Holdings announced that as a result of continued positive discussions with the Company's senior secured lenders, the Company expects to enter into an agreement securing additional liquidity and receiving a forbearance from its senior secured lenders regarding certain previous events of default. The Company expects to finalize the agreement with its senior secured lenders next week, although no assurance can be made that an agreement will result from these discussions within that time frame or that an agreement consistent with these discussions will be reached at all.

06:15 EDT PG&E warns it could cut power to California users again - Pacific Gas and Electric Company said in a statement on Monday that since Sunday, its emergency operations center has been open and teams have been monitoring a dry, offshore wind event. On Monday, the company began its 48-hour advance notifications to customers that it may be proactively turning power off for safety and conducting a Public Safety Power Shutoff on late Wednesday evening. The potential safety shutoff is planned for varying start times depending on location beginning Wednesday evening and is expected to affect approximately 209,000 customers and may impact portions of 15 counties in the Sierra Foothills and the North Bay, including Amador, Butte, Calaveras, El Dorado, Lake, Mendocino, Napa, Nevada, Placer, Plumas, San Mateo, Sierra, Sonoma, Sutter, and Yuba. "The sole purpose of PSPS is to significantly reduce catastrophic wildfire risk to our customers and communities. We know that sustained winds above 45 mph are known to cause damage to the lower-voltage distribution system and winds above 50 mph are known to cause damage to higher-voltage transmission equipment. As we saw in the last PSPS event, we had more than 100 instances of serious damage and hazard on our distribution and transmission lines from wind gusts of this strength," said Michael Lewis, Senior Vice President, PG&E Electric Operations.

06:08 EDT Tile Shop suspends dividend, cancels share repurchase program - The Board of Directors decided to suspend the company's quarterly cash dividend and cancel the company's share repurchase program, each effective immediately, to focus on debt reduction and continued investment in strategic initiatives.

06:07 EDT Tile Shop announces plans to delist from Nasdaq - Tile Shop announced that it will voluntarily delist its common stock from the Nasdaq Stock Market, and based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934 and suspend its public reporting obligations. Cabell Lolmaugh, the company's CEO, stated, "We've undertaken a thorough and thoughtful review of our cost structure, including costs associated with being a Nasdaq-listed and SEC reporting company. After careful consideration, our Board of Directors decided to voluntarily delist from Nasdaq and deregister with the SEC as we believe the savings that will benefit our shareholders outweigh the advantages of continuing as a Nasdaq-listed and SEC reporting company."

06:05 EDT Tile Shop reports Q3 Comparable Store Sales down 3.5% -

06:03 EDT Centene, WellCare announce approval of pending transaction by NYS - Centene (CNC) and WellCare Health Plans (WCG) announced that the New York Department of Financial Services and Department of Health have each approved Centene's pending indirect acquisition of New York domiciled WellCare insurance subsidiaries, bringing the total number of states to approve the transaction to 25. The companies continue to expect that the transaction will be completed by the first half of 2020. Completion of the transaction remains subject to clearance under the Hart-Scott-Rodino Act, receipt of the remaining required state regulatory approvals and other customary closing conditions.

05:41 EDT Carlisle to acquire Draka Fileca - Carlisle Companies announced it has submitted an irrevocable and binding offer and entered into exclusive discussions to acquire 100% of the shares of Draka Fileca SAS from Prysmian SpA. The purchase of Draka Fileca is consistent with Carlisle's Vision 2025 strategy to build scale with synergistic acquisitions to drive to $15 of earnings per share. Draka Fileca would become part of the Carlisle Interconnect Technologies operating segment. The contemplated acquisition is subject to the required information and consultation processes with French employee representative bodies and other regulatory approvals. Closing of the transaction is expected to occur no later than during Q1 of 2020.

05:38 EDT TechnipFMC awarded iEPCI contract for Shell Perdido Phase 2 Development - TechnipFMC has been awarded an integrated Engineering, Procurement, Construction and Installation, or iEPCI, contract by Shell for the Perdido Phase 2 development, located in the Gulf of Mexico. The contract covers the delivery and installation of subsea equipment, including flexible flowlines, flexible jumpers, steel flying leads, electrical flying leads, and will utilize compact manifold technology, with the Subsea 2.0 In-Line Compact Manifold.